Xerclear, Medivir’s proprietary cream formulation, is a topical product indicated for the treatment of recurrent herpes labialis.
As part of the distribution agreement, Daewoong will conduct clinical trials and will be responsible to market, sell and distribute Xerclear in those regions.
Daewoong will also seek regulatory approvals for Xerclear.
In connection with this, Daewoong has recently filed for registration with the South Korean authorities and expects the regulatory approval later this year.
Medivir president and CEO Ron Long said they look forward to continue to work closely with Daewoong and the launch of Xerclear in South Korea early next year.